Tag: biosimilar vs generic
Biologic Patent Protection: When Biosimilars Can Enter the Market
Explore how biologic patent protection under the BPCIA delays biosimilar entry. Learn about the 12-year exclusivity, the patent dance, and the growing biosimilar void affecting drug prices.
Read more
Biosimilar Approval: How the FDA Reviews Biologic Alternatives in 2025
The FDA's 2025 guidance streamlines biosimilar approval by reducing the need for costly clinical trials, relying instead on advanced analytical data. This shift could cut costs, speed up access, and boost competition in the biologic drug market.
Read more